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Microribonucleic Acids for Prevention
of Plaque Rupture and In-Stent Restenosis
“A Finger in the Dam”
John F. O’Sullivan, MD, Kenneth Martin, PHD, Noel M. Caplice, MD, PHD
Cork, Ireland
Vascular smooth muscle cells (VSMCs), which make up the arterial medial layer, possess a phenotype switching
capability. This modulation of VSMCs is important in the development of atherosclerotic vascular disease. It has
been recognized that VSMCs may also have a stabilizing role in advanced atherosclerotic plaques. Moreover,
reduction of the proliferative capacity of these cells may be of benefit in reducing neointimal hyperplasia follow-
ing therapeutic percutaneous intervention. The biology of microribonucleic acids (miRNAs) and their ability to
modify smooth muscle biology has recently emerged in a number of investigations. These studies elucidated the
key role of miRNAs, miR-143 and miR-145, in particular, in the regulation of SMC homeostasis in vitro, in mu-
rine models of targeted gene deletion, and also in human vascular pathology. This review places this burgeoning
knowledge within the wider context of atherosclerosis and restenosis and explores the therapeutic potential of
miRNAs to change the fate of VSMCs within the plaque. (J Am Coll Cardiol 2011;57:383–9) © 2011 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.029m
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-icroribonucleic acids (miRNAs) are an emerging class of
ighly conserved, noncoding small RNAs (20 to 25 nucleo-
ides) that regulate gene expression at the post-transcriptional
evel, inhibiting the translation of protein from messenger
NA (mRNA) by promoting the degradation of mRNA
1). miRNAs are key regulators of many cellular events,
ncluding the balance between proliferation and differenti-
tion during tumorigenesis and organ development (1–3).
ore than 600 human miRNAs have been identified so far,
nd it is proposed that they regulate over 50% of human
rotein-coding genes (4). They can be located in introns of
oding genes or noncoding genes or in exons and their
ranscription depends on the host gene (5,6). miRNAs that
ave their own promoters are independently expressed, and
hose that are organized in clusters share the same transcrip-
ional regulation (7,8). Once they are expressed, their
aturation is mediated by the 2 ribonuclease III endonucle-
ses Dicer and Drosha (9) (Fig. 1A). The mature miRNA
ncorporates into the RNA-induced silencing complex (10),
hich directs it to the target mRNA, leading to the latter’s
ranslational repression or degradation (9).
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ccepted September 21, 2010.iR-143 and -145 in
mooth Muscle Differentiation
breakthrough in the smooth muscle biology field occurred
n 2009 with the emergence of a number of key observa-
ions, concerning the role of miRNAs (miR-143 and -145)
n the regulation of smooth muscle differentiation in vitro,
s well as phenotypic characterization in a murine model of
argeted deletion of the miR-143/145 gene cluster (11). The
onclusions from these studies are in broad agreement
egarding how miR-143/145 affect the canonical balance
etween the synthetic/proliferative and the contractile/
ifferentiated states in vascular smooth muscle cells
VSMCs) (11–14).
In general, contractile smooth muscle proteins such as
lpha-smooth muscle actin, smooth muscle myosin heavy
hain, SM22-alpha, desmin, and calponin contain CArG
CC(A/T)6GG] elements in the promoter-enhancer region
f the gene (15–21). Serum response factor binds the CArG
oxes and this drives transcription (20), and in VSMC
ifferentiation, the serum response factor binds its coacti-
ator myocardin (22) in a 2:1 stoichiometric ratio thus
nducing CArG-dependent VSMC gene transcription (23).
yocardin is now considered to be the master gene regu-
ating VSMC differentiation (24) (Fig. 1B).
In their initial report, Cordes et al. (12) identified
iR-145 and -143 as having a key role in the regulation of
SMC phenotype. Myocardin up-regulates miR-143 and
145 expression and introduction of these miRNAs potenti-
ted myocardin-induced smooth muscle marker gene expres-
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miRNAs and VSMC in Plaques and Restenosis January 25, 2011:383–9sion, myofilament formation,
and calcium fluxes in response to
endothelin-1. The repressor of
myocardin-directed smooth mus-
cle gene expression KLF4 (which
binds myocardin) was identified
as a target of miR-145 in murine
VSMC (12). Human KLF4
mRNA contains no binding site
for miR-143 and only a low proba-
bility site for miR-145 (TargetScan
5.1, Whitehead Institute for Bio-
medical Research, Cambridge,
Massachusetts). However, KLF5
Abbreviations
and Acronyms
CArG  CC(A/T)6GG
ISR  in-stent restenosis
miRNA  micro-ribonucleic
acid
mRNA  messenger
ribonucleic acid
PDGF  platelet-derived
growth factor
VSMC  vascular smooth
muscle cell
Figure 1 Summary of miRNA Maturation and Translation, and t
VSMC Function and its Therapeutic Potential
(A) Microribonucleic acid (miRNA) maturation and inhibition of messenger ribonucl
which targets specific mRNAs for degradation. (B) MiR-143/145 promotes smooth
din/SRF-dependent vascular SMC gene expression. Dashed green arrows represe
muscle cell (VSMC) dedifferentiation context. (C) Therapeutic potential of miR-143
increased integrin expression and focal adhesions between VSMCs in the fibrous
tic potential of miR-143/145 in in-stent restenosis: a reduction in VSMC proliferat
ribonucleic acid–induced silencing complex; pre-miRNA  previous miRNA; pri-miRs highly conserved across human, mouse, and rat protein
equences and does contain a binding site for miR-145.
urthermore, it has been demonstrated that vascular injury
auses down-regulation of miR-145, which up-regulates
LF5 and inhibits myocardin, leading to VSMC dediffer-
ntiation and increased neointimal lesion formation (13).
oth smooth muscle marker gene and miR-145 expression
ere repressed by platelet derived growth factor (PDGF)-
eta, a known smooth muscle proliferative stimulant, in a
urine model of wire-mediated vascular injury. Accord-
ngly, miR-145 is expressed in smooth muscle, but not
ndothelial cells and its expression pattern correlates with a
ifferentiated phenotype as defined by alpha-smooth muscle
ctin, smooth muscle myosin heavy chain, and calponin
fects of miR-143/145 on
id (mRNA) translation through formation of a miRNA-induced silencing complex,
le cell (SMC) differentiation by inhibiting KLF5-mediated repression of myocar-
otion; solid red lines indicate direct inhibition in a pathological vascular smooth
in atherosclerotic plaques: increased miR-143/145 expression may lead to
us promoting fibrous cap integrity and, therefore, plaque stability. (D) Therapeu-
acity induced by miR-143/145 may reduce in-stent restenosis. miRISC  micro-
rimary miRNA.he Ef
eic ac
musc
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January 25, 2011:383–9 miRNAs and VSMC in Plaques and Restenosisxpression (13). Induction of miR-145 by pre-miR-145–
nhanced smooth muscle marker gene expression and myo-
lament formation in SMCs. This role of miRNAs in
SMC differentiation is summarized in Figure 1B.
Boettger et al. (11) also demonstrated a central role for
he miR-143/145 cluster in VSMC phenotypic modulation
n a study that also focused on a miR-143/145 cluster
nockout mouse. In their study, at baseline, SMCs from
iR-143/145–/– mice lacked expression of contractile mark-
rs calponin and smoothelin compared with wild-type
SMC. Ultrastructural electron microscopic analysis
howed greater presence of rough endoplasmic reticulum
nd less focal adhesions in miR-143/145–deficient VSMC
ith the converse in wild-type cells. These differences were
ssociated with impaired contractility of femoral artery rings
n response to high K, angiotensin II, and phenylephrine.
ccording to this report, miR-143/145–/– mice also had a
endency to develop neointimal lesions. Aortic VSMCs from
he double knockout mouse lacked myofilamentous cytoskel-
tal organization and had diffuse actin staining. Although
re-clinical studies using rodent models can yield very useful
echanistic insight, the genetic differences between these
pecies and humans must be taken into account when trans-
ating their relevance to the clinical setting. The relevance of
iR-143/145 in human vessel pathology was suggested by
own-regulation of the miR-143/145 cluster in human aortic
neurysms by comparison with normal aortic tissue as assessed
y quantitative reverse transcriptase polymerase chain reaction
14), suggesting a role for these microRNAs in maintaining
essel homeostasis. More thorough characterization of the
iR-143/145 effects in human VSMC is now required.
SMCs, the Fibrous Cap, and Plaque Stability
n humans, ruptured atherosclerotic plaques show a paucity
f VSMCs compared with stable lesions (25), indicating
hat VSMCs contribute to plaque stability (26). Indeed
SMCs are the only cells capable of synthesizing compo-
ents of the fibrous cap in plaques, which separates circu-
ating blood from the thrombogenic plaque interior (25).
Vulnerable plaque is defined as a plaque that is at high risk
f rupture and is the “short-term pre-cursor” to the culprit
laque in acute coronary syndromes (27–29). Although
rediction of vulnerable plaques is still elusive, selective
harmacological modulation of VSMC phenotype may
mprove their stability. Promoting a quiescent VSMC
henotype may therefore lead to increased fibrous cap
ntegrity, and in this respect, miRNAs may offer an oppor-
unity for positive VSMC regulation (Fig. 1C).
The role of the VSMC varies depending on the stage of
therosclerotic disease, with VSMCs playing a maladaptive
ole in early lesion development and progression (30,31). In
ontrast, VSMCs may play a beneficial adaptive role within
he fibrous cap by stabilizing advanced plaques in the face of
nd-stage disease events such as plaque rupture (32,33). The
ontribution of VSMCs to atherosclerosis includes produc- cion of various proteases (33), as well as extracellular matrix
roduction (34–36), participation in chronic inflammatory
esponses including production of inflammatory cytokines
nd expression of at least some inflammatory cell markers
37–39), altered contractility, and expression of contractile
roteins (40,41). Massive VSMC apoptosis occurs after
njury (42) and chronic, low-level VSMC death also char-
cterizes arterial aneurysms, where medial VSMC loss,
nflammation, fragmentation of elastin, and matrix degra-
ation lead to progressive dilation and potential rupture
43). The concept that VSMCs play an important role in
laque stability is reinforced when considering the conse-
uences of VSMC death, which increases as atherosclerotic
laques develop (44). Together these data implicate the
nvolvement of VSMC apoptosis in plaque rupture (45).
herapeutic Potential of miRs
or Plaque Stabilization
henotypic modulation of VSMCs is proposed as an im-
ortant cellular event in the development of atherosclerotic
ascular disease. If achieved using miR-143/145, 2 impor-
ant clinical consequences at different stages of plaque
evelopment could result: 1) a decrease in VSMC prolifer-
tion within immature atherosclerotic plaques; and 2) fi-
rous cap stabilization in more advanced plaques. From a
linical viewpoint, this modulation has a potential role in
revention of coronary, and indeed peripheral, arterial
isease. The consequences of plaque rupture are most clearly
een in the coronary and cerebrovascular circulations.
herefore, individuals with a heavy atherosclerotic burden,
r those with significant cardiovascular risk factors, that may
r may not have had a previous vascular event, would also
enefit from such therapy.
Unlike many terminally differentiated cells, VSMCs can
witch between differentiated and dedifferentiated pheno-
ypes in response to changes in the local environment (46).
he recent identification, by Cordes et al. (12), of miR-145
nd -143 as having a key role in the regulation of VSMC
henotype, both in terms of proliferation and differentia-
ion, provides an opportunity for targeting noncoding se-
uences such as miRs through gene therapy. Extrapolating
rom Boettger et al. (11), up-regulation of miR-145 and
143, for example, by use of pre-miR-145/143 and its
anking sequence, could potentially lead to expression of
ore integrins and focal adhesions, thereby strengthening
he fibrous cap. Furthermore, promotion of the less syn-
hetic, contractile SMC expressing more calponin and
moothelin markers could decrease the rate at which more
mmature atherosclerotic lesions develop (Fig. 1C).
Other miRNAs with the potential to modulate athero-
clerotic plaques include miR-126, which confers plaque
tability and decreases the rate of atherosclerosis progression
47). During plaque development, endothelial cell-
erived apoptotic bodies are generated that convey para-
rine alarm signals to recipient vascular cells that trigger
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miRNAs and VSMC in Plaques and Restenosis January 25, 2011:383–9he production of CXCL12. The production of CXCL12
ediated by miR-126 enabled CXCR4 to trigger an
utoregulatory feedback loop that further increased the
ynthesis of CXCL12. Administration of apoptotic bod-
es, or miR-126, limited atherosclerosis, promoted the
ncorporation of Sca-1 progenitor cells, and conferred
eatures of plaque stability in a number of different
therosclerosis models (47).
SMCs and In-Stent Restenosis
SMCs play a central role in in-stent restenosis (ISR),
hich is reviewed in Mitra and Agrawal (48). Briefly, the
ascular injury induced by stent implantation gives rise to
ocal apoptosis of medial VSMC (49). The ensuing regen-
rative repair response involves the coordination of many
lements including thrombus deposition and leukocyte traf-
cking to the stent site, growth factors such as PDGF-beta
50), eicosanoids such as thromboxane A2 (51), local throm-
in generation (52), and vasoactive agents such as angio-
ensin II (53), all of which are known VSMC mitogenic
timuli with the latter 2 both signaling through G-alpha-
-coupled receptors. The dysregulation of this repair re-
ponse may lead subsequently to excessive VSMC prolifer-
tion and, therefore, the formation of a stenotic lesion that
ncroaches upon the vessel lumen (54). PDGF-beta, one of
he most potent VSMC mitogens, induces a proliferation
timulus via biphasic extracellular signal-regulated kinase acti-
ation in addition to phosphoinositide-3 kinase and Akt
ctivation, which downstream results in cell cycle progression
hrough G1/S (55). Within the first 18 months following
tenting, the VSMC content (determined by alpha-smooth
uscle actin staining) of the neointimal lesion is around 66%,
hich reduces to 12% thereafter, which is indicative of a
reater extracellular matrix component (determined by colla-
en I and III staining) within the lesion (56). VSMC under
ransforming growth factor-beta stimulation are the major
roducers of proteoglycan-rich extracellular matrix in neoin-
ima (57), which contributes to lesion size in the later phases.
herefore, the initiation of the proliferative state in VSMC
ccurring with phenotypic switching may represent an ideal
pportunity for therapeutic intervention (Fig. 1D).
odification of in-stent restenosis by miRs. There are
miRs implicated in modification of vessel restenosis after
nterventional endothelial injury: miR-21, -145, and -221. Ji
t al. (58) demonstrated that antisense knockdown of
iR-21, which they also revealed is moderately increased
fter vessel injury, blunted the formation of a neointimal
esions in response to balloon injury of the carotid artery.
urthermore, miR-21 promoted VSMC proliferation after
essel injury via activation of Akt and Bcl-2 with concom-
tant inhibition of phosphatase-and-tensin-homology-
eleted-from-chromosome-10, the latter being a putative
arget for silencing by miR-21 (58). A general miRNA-21
nhibition was also shown to be beneficial in terms of heart
ailure, especially attenuation of fibrosis (59). It should be aoted that miR-21 inhibition also improved function of
mpaired endothelial progenitor cells especially in patients
ith coronary artery disease and high risk for neointima
ormation (60). Adenovirus-mediated overexpression of
iR-145 promoted VSMC marker expression and reduced
eointima formation in response to rat carotid balloon
njury (13). miR-221 was induced in VSMCs on PDGF-
eta stimulation, which caused: 1) down-regulation of cKit,
esulting in a decrease in SMC differentiation; and 2)
27Kip1 inhibition, which increased SMC proliferation
61), both of which contribute to the formation of a
eointimal lesion after arterial injury.
Therefore, knockdown of miR-21, miR-221, and over-
xpression of miR-145 may block neointima formation after
essel injury.
herapeutic Approaches for miRs:
trategies, Delivery, and Complications
o date, very few gene therapy studies delivering an
ntracoronary agent have been carried out in humans (62).
owever, those performed suggested that this is a safe and
easible therapeutic strategy, with potential benefits in terms
f anti-ischemic end points reported. The AGENT (An-
iogenic GENe Therapy)-1, -2, -3, and -4 trials (63–65)
nvolved intracoronary delivery of a replication defective
denovirus containing a human fibroblast growth factor
ene that showed some promising anti-ischemic potential in
atients with angina pectoris. Intracoronary gene transfer
eading to improved myocardial perfusion without increased
estenosis rate at 6 months was performed in the KAT
Kuopio Angiogenesis Trial) (66), which involved local
ascular endothelial growth factor gene transfer during
ngioplasty and stenting. Although routine use of intracoro-
ary gene therapy is years away, the use of miRs to enhance
therosclerotic plaque stability or prevent ISR offer some
romise as therapeutic agents based on the laboratory
nvestigations already carried out.
There are several possibilities to overcome the obstacles that
xist in the delivery of miR-143/145–based therapeutics.
arious chemical modifications of the nucleotides can enhance
tability in vivo (67), such as in the first mammalian anti-miR
nockdown reported by Krützfeldt et al. (68) using cholesterol-
onjugated, 2=-O-methyl–modified “antagomiRs” that re-
ulted in derepression of putative target mRNAs. So far in
nimal studies, intravenously injected antagomiRs and miR
imetics have been the primary method of systemic delivery
59,69–73) and have demonstrated effects on myocardial
emodeling; however, they are preferentially targeted to the
iver, kidney, and spleen. Therefore, enrichment of miR-based
gents in the coronary vasculature may be a major challenge.
trategies might include conjugation of the nucleic acid to
argeting molecules such as peptides, antibodies, or other
ioactive molecules, which may promote homing of the
iRNA-based agents to the site of vascular injury. The specificpplication of the agent to the coronary vasculature during
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January 25, 2011:383–9 miRNAs and VSMC in Plaques and Restenosisardiac catheterization may also be an effective therapeutic
pproach.
Another significant challenge is the platform for delivery.
hereas previously, the delivery of miRNAs would have
elied on direct naked/nonviral deoxyribonucleic acid plas-
id injection or viral-mediated gene transfer (74,75), syn-
hetic vehicles consisting of a double-stranded polynucle-
tide, a lipid moiety to facilitate entry into the cell, and pH
abile bonds allowing release of the polynucleotides may
llow efficient in vivo delivery of miRNA-based therapeutics
76). The most relevant miR human study up to now
nvolved delivery of oligodeoxynucleotides (77) targeting
roliferation in autologous vein grafts, by interfering with
he E2F transcription factor that regulates cell cycle pro-
ression effectively “ex vivo” (78). This resulted in inhibition
f graft occlusion associated with selective inhibition of
roliferating cell nuclear antigen and c-myc expression. In
he PREVENT II (Program in Ex Vivo Vein Graft Engi-
eering Via Transfection II Study: E2F Decoy in CABG)
andomized, double-blind, placebo-controlled trial (79), the
afety and feasibility of E2F decoy oligonucleotides in
reventing autologous vein graft neointimal hyperplasia and
therosclerosis after coronary artery bypass surgery was
emonstrated. In the acute infarct setting, however, thera-
eutic administration, either before or after reperfusion
emains a challenge. However, this is a clinical scenario that
emands careful attention and holds potentially the greatest
eward. Use of a polymer-coated stent coupled with a
ynthetic miRNA-vehicle-complex would allow delivery of
he miRNA at the time of infarct, with a potential 3-fold
enefit—stabilizing the ruptured plaque, slowing progres-
ion of “target vessel” disease, and prevention of ISR—
imultaneously addressing the most significant issues of the
echanical coronary intervention era.
Given the far-reaching and ever-expanding roles of
iRNAs, it will be necessary to explore the potential
dverse consequences of therapeutic miRNA manipulation.
pecific miRNAs have been linked to cancer, and interest-
ngly, mature miRNA levels of miR-143 and -145 are
educed in colorectal tumors as well as many cancer cell lines
80,81), suggesting that therapies that increase levels of
hese miRNAs, theoretically at least, will not have neoplas-
ic potential. Furthermore, the tumor-suppression activity
f miR-145 has been shown to be expressed through the
hosphoinositide-3 kinase/Akt and p53 pathways (82).
iR-126, which inhibits progression of atherosclerosis and
ncreases plaque stability in a mouse model, was shown by
rawford et al. (83) to inhibit invasion in non–small cell
ung carcinoma cell lines through regulation of the Crk
daptor protein. miR-221 has been implicated as a potential
ncogene in papillary thyroid carcinoma (84) and grade II to
V astrocytic tumors (85); however, its down-regulation to
ecrease ISR may be a safe therapeutic option. Knockdown
f miR-21 is associated with decreased neointimal forma-
ion post-carotid balloon injury (58). Likewise, miR-21 is
mplicated as an oncogene; therefore, it seems this isnother miRNA that may be safely inhibited to decrease
SR without neoplastic consequences.
onclusions
he recent emergence of miRNAs and the subsequent
iscovery of their key role in the VSMC homeostasis
resent an opportunity to change the fate of VSMCs and
hus influence vascular biology. The ubiquitous presence of
SMCs in the fibrous cap of advanced atherosclerotic
laques in addition to their pivotal role in the progression of
SR identify these cells as an important target in modulating
ascular disease. There has been substantial progress re-
ently in manipulating expression of miRNAs, but the
pecific miRNAs implicated in VSMC phenotypic switch-
ng have not been targeted therapeutically. Given the recent
iscovery that miRNAs regulate the genome to a much
reater degree than originally thought, there must be a
egree of caution when manipulating such influential non-
oding sequences. Although tumorigenesis is one of the
reatest concerns associated with miRNA manipulation,
p-regulation of miR-143/145 appears to be a theoretically
afe option and may have multiple potential benefits in
erms of plaque stabilization and reduction in atherosclero-
is. Manipulation of VSMC-associated miRNAs, therefore,
resents an excellent opportunity for cardiologists and
ascular biologists alike and is an exciting potentially new
herapeutic option for atherosclerotic plaque and its com-
lications including ISR.
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